PRLD Prelude Therapeutics
- 4.010
- +0.150+3.89%
Prelude Therapeutics News
Prelude Therapeutics to Participate in Citizens JMP Life Sciences Conference
WILMINGTON, Del., May 09, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (NASDAQ:PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in the
Barclays Sticks to Its Hold Rating for Prelude Therapeutics (PRLD)
Buy Rating Affirmed for Prelude Therapeutics on Strong Financials and Promising Clinical Prospects
Prelude Therapeutics | 10-Q: Quarterly report
Express News | Prelude Therapeutics Inc - Current Cash Runway Into 2026
Prelude Therapeutics 1Q Loss/Shr 42c >PRLD
Prelude Therapeutics 1Q Loss/Shr 42c >PRLD
Press Release: Prelude Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
Prelude Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update First-in-class IV SMARCA2 degrader, PRT3789 and potentially best-in-class CDK9 inhibitor, PRT2527 remai
Express News | Prelude Therapeutics Q1 Operating Expenses USD 34.343 Million
Express News | Prelude Therapeutics Q1 EPS USD -0.42 Vs. Ibes Estimate USD -0.48
Express News | Prelude Therapeutics Q1 Income From Operations USD -34.343 Million
Express News | Prelude Therapeutics Q1 Net Income USD -31.431 Million
Express News | Prelude Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
Prelude Therapeutics: Leading the Oncology Market With Innovative SMARCA2 Targeting Drug PRT3789
Here's Why We're Watching Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Situation
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the right price. For example, biotech and mining exploration companies often lose mo
Several Insiders Invested In Prelude Therapeutics Flagging Positive News
Prelude Therapeutics Announces CFO Transition and Interim Appointment
Express News | Prelude Therapeutics Disclosed Laurent Chardonnet Will No Longer Serve As CFO
Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual Meeting
Highly selective oral SMARCA2 degrader, PRT7732, shows robust anti-tumor activity in vivo as monotherapy and in combination with chemotherapy, at well-tolerated doses Potentially best-in-class CDK9 inhibitor, PRT2527,
Prelude Therapeutics Initiated at Market Outperform by JMP Securities
Prelude Therapeutics Initiated at Market Outperform by JMP Securities
Express News | JMP Securities Initiates Coverage On Prelude Therapeutics With Market Outperform Rating, Announces Price Target of $7
Analysis
Price Target
No Data
